KBC Group NV Sells 248,320 Shares of Edwards Lifesciences Co. (NYSE:EW)

KBC Group NV trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 27.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 647,842 shares of the medical research company’s stock after selling 248,320 shares during the quarter. KBC Group NV owned 0.11% of Edwards Lifesciences worth $47,959,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. grew its holdings in shares of Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after buying an additional 273 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in shares of Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Piper Sandler lowered their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Robert W. Baird decreased their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price for the company. in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Stock Up 0.3 %

EW stock opened at $69.21 on Tuesday. The business’s fifty day moving average price is $72.33 and its two-hundred day moving average price is $70.36. The stock has a market capitalization of $40.82 billion, a price-to-earnings ratio of 9.99, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.